Lck Inhibitor is a potent, orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor used for:
- Inhibiting T-cell receptor-induced IL-2 secretion (IC₅₀ = 0.46 μM) and subsequent T-cell proliferation (IC₅₀ = 0.53 μM) in human T-cells;
- Suppressing human mixed lymphocyte reaction (huMLR) with enhanced potency compared to other in vitro assays using purified human cells;
- Inhibiting Lck-dependent T-cell receptor (TCR) chain phosphorylation in a mechanism-based cellular assay;
- Attenuating arthritis in an adjuvant-induced arthritis model in male Lewis rats in a dose-dependent manner (ED₅₀ ≈ 24 mg/kg);
- Serving as a selective inhibitor of Lck over other kinase families (e.g., MAPK, CDK, RSK), with >1000-fold selectivity.